DNIB Unwind Company Profile (NASDAQ:BIND)

About DNIB Unwind

DNIB Unwind logoDNIB Unwind, Inc., formerly BIND Therapeutics, Inc. is a shell company. The Company was engaged in developing targeted therapeutics, primarily for the treatment of cancer. As of August 1, 2016, the Company sold all of its assets. The Company's subsidiaries include BIND (RUS) LLC and DNIB Subsidiary Corporation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BIND
  • CUSIP:
Key Metrics:
  • Previous Close: $0.87
  • 50 Day Moving Average: $0.52
  • 200 Day Moving Average: $1.17
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.80
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 2.79
Additional Links:
Companies Related to DNIB Unwind:

Analyst Ratings

Consensus Ratings for DNIB Unwind (NASDAQ:BIND) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $5.25 (503.45% upside)

Analysts' Ratings History for DNIB Unwind (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetDetails
7/6/2016Stifel NicolausReiterated RatingHoldView Rating Details
4/7/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
4/7/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
4/7/2016Oppenheimer Holdings, Inc.DowngradeMarket PerformView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$9.00 -> $6.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for DNIB Unwind (NASDAQ:BIND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016        
5/9/2016Q116($0.55)($0.61)$3.83 million$1.87 millionViewListenView Earnings Details
3/15/2016Q415($0.49)($0.37)$3.35 million$6.40 millionViewListenView Earnings Details
11/2/2015Q315($0.52)($0.49)$3.14 million$2.10 millionViewN/AView Earnings Details
8/6/2015Q215($0.51)($0.51)$3.88 million$2.50 millionViewListenView Earnings Details
5/7/2015Q115($0.51)($0.44)$2.67 million$4.40 millionViewListenView Earnings Details
3/11/2015Q414($0.40)($0.51)$6.00 million$3.00 millionViewListenView Earnings Details
11/6/2014($0.31)($0.44)ViewN/AView Earnings Details
8/7/2014Q214($0.60)($0.51)$2.20 million$2.46 millionViewN/AView Earnings Details
5/9/2014($0.49)($0.51)ViewN/AView Earnings Details
3/25/2014($0.41)($0.50)ViewN/AView Earnings Details
11/5/2013Q313($0.67)($2.70)$1.66 million$4.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for DNIB Unwind (NASDAQ:BIND)
Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.61)($0.58)($0.60)
Q2 20162($0.48)($0.46)($0.47)
Q3 20162($0.48)($0.46)($0.47)
Q4 20162($0.49)($0.47)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for DNIB Unwind (NASDAQ:BIND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for DNIB Unwind (NASDAQ:BIND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2013Noubar AfeyanDirectorBuy20,000$15.00$300,000.00View SEC Filing  
9/25/2013Polaris Venture Management Co.Major ShareholderBuy26,000$15.00$390,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for DNIB Unwind (NASDAQ:BIND)
DateHeadline
News IconBIND Therapeutics, Inc. (NASDAQ:BIND) Under Analyst Spotlight - UK Market News (NASDAQ:BIND)
www.ukmarketnews.co.uk - February 16 at 5:31 AM
News IconReviewing Individual Broker Targets Of BIND Therapeutics, Inc. (NASDAQ:BIND) - NewsDen (NASDAQ:BIND)
newsden.net - February 4 at 3:59 PM
News IconI WANT TO BUY ZITHROMAX - Rhine Inc India - Generic Viagra Pro - 9,419 Orders Today (NASDAQ:BIND)
www.wholereason.com - January 19 at 3:23 PM
publicnow.com logoBIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc. (NASDAQ:BIND)
www.publicnow.com - January 3 at 4:22 PM
finance.yahoo.com logoBIND Therapeutics Announces Two Bidders Join Pfizer’s Stalking Horse Bid in Auction for BIND’s Assets (NASDAQ:BIND)
finance.yahoo.com - January 3 at 4:22 PM
publicnow.com logoBIND Therapeutics Announces Two Bidders Join Pfizer's Stalking Horse Bid in Auction for BIND's Assets (NASDAQ:BIND)
www.publicnow.com - January 3 at 4:22 PM
finance.yahoo.com logoBIND Therapeutics Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets (NASDAQ:BIND)
finance.yahoo.com - January 3 at 4:22 PM
publicnow.com logoBIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets (NASDAQ:BIND)
www.publicnow.com - January 3 at 4:22 PM
News IconVaping Banned Within Prestonsburg City Limits (NASDAQ:BIND)
vapenewsmagazine.com - December 4 at 10:29 AM
marketexclusive.com logoDNIB UNWIND, INC. (OTCMKTS:BINDQ) Files An 8-K Other Events - Market Exclusive (NASDAQ:BIND)
marketexclusive.com - November 30 at 3:54 PM
News IconImportant Short Interest Filing: Is INTERCLOUD SYSTEMS INCORPORATED (ICLD) a Buy? The Stock Is in Investors ... - Thorold News (NASDAQ:BIND)
www.whatsonthorold.com - October 27 at 4:08 PM
News IconImportant Short Interest Filing: Is INTERCLOUD SYSTEMS INCORPORATED (ICLD) a Buy? The Stock Is in Investors ... - Thorold News (NASDAQ:BIND)
www.whatsonthorold.com - October 27 at 4:08 PM
seekingalpha.com logoMedical Marijuana Offers Opportunities For The Daring Investor - Seeking Alpha (NASDAQ:BIND)
seekingalpha.com - October 27 at 4:08 PM
seekingalpha.com logoMedical Marijuana Offers Opportunities For The Daring Investor - Seeking Alpha (NASDAQ:BIND)
seekingalpha.com - October 27 at 4:08 PM
sg.finance.yahoo.com logoBind Therapeutics reports 2Q loss (NASDAQ:BIND)
sg.finance.yahoo.com - October 27 at 4:08 PM
istreetwire.com logoInvestor's Alert: Community Health Systems, Inc. (CYH), Synergy Pharmaceuticals, Inc. (SGYP), General Dynamics ... - iStreetWire (NASDAQ:BIND)
istreetwire.com - October 27 at 8:20 AM
sbwire.com logoNovel Drug Delivery Systems - NDDS in Cancer Therapyis Expected to Reach USD 15,984.2 Million in 2020 (NASDAQ:BIND)
www.sbwire.com - October 26 at 3:52 PM
News IconPeptide Therapeutics Market is expected to fuel the market growth over the forecast period (NASDAQ:BIND)
globalmarketresearchinsight.wordpress.com - October 26 at 12:48 PM
4-traders.com logoTelesta Therapeutics : shareholders approve plan of arrangement with ProMetic Life Sciences Inc. (NASDAQ:BIND)
www.4-traders.com - October 25 at 9:03 PM
marketexclusive.com logoGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Files An 8-K - Market Exclusive (NASDAQ:BIND)
marketexclusive.com - October 25 at 3:52 PM
4-traders.com logoGlobal Blood Therapeutics : Announces Pivotal Study for GBT440 in Sickle Cell Disease with Primary Hemoglobin Endpoint (NASDAQ:BIND)
www.4-traders.com - October 25 at 8:41 AM
fool.com logoBetter Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc. - Motley Fool (NASDAQ:BIND)
www.fool.com - October 18 at 8:40 AM
streetinsider.com logoForm S-8 POS DNIB UNWIND, INC. - StreetInsider.com - StreetInsider.com (NASDAQ:BIND)
www.streetinsider.com - October 15 at 8:40 AM
streetinsider.com logoForm 8-K DNIB UNWIND, INC. For: Oct 11 - StreetInsider.com (NASDAQ:BIND)
www.streetinsider.com - October 11 at 3:53 PM
istreetwire.com logoStocks in Focus: Synergy Pharmaceuticals, Inc. (SGYP), Allergan plc (AGN), Sunstone Hotel Investors Inc. (SHO) - iStreetWire (NASDAQ:BIND)
istreetwire.com - October 7 at 8:41 AM
globenewswire.com logoNanotechnology Drug Delivery Market to reach US$ 11.9 Billion in 2023; Transparency Market Research - GlobeNewswire (press release) (NASDAQ:BIND)
globenewswire.com - September 29 at 3:22 PM
News IconNanotechnology Drug Delivery Market to reach US$ 11.9 Billion in 2023 Transparency Market Research - EconoTimes (NASDAQ:BIND)
www.econotimes.com - September 28 at 8:39 AM
finance.yahoo.com logoNanotechnology Drug Delivery Market to reach US$ 11.9 Billion in 2023; Transparency Market Research (NASDAQ:BIND)
finance.yahoo.com - September 27 at 3:52 PM
News IconBIND Therapeutics Bankruptcy Plan Confirmed (NASDAQ:BIND)
bankruptcompanynews.com - September 27 at 3:52 PM
News IconDNIB Unwind Inc (OTCMKTS:BINDQ) OTC Stock Update - The Oracle Dispatch (NASDAQ:BIND)
oracledispatch.com - September 27 at 8:26 AM
News IconBIND Therapeutics Bankruptcy Plan Confirmed - Bankrupt Company News (press release) (blog) (NASDAQ:BIND)
bankruptcompanynews.com - September 27 at 8:26 AM
News IconGlobal Nanotechnology Drug Delivery Market Gains from Rising Demand for Technically Advanced Drug Delivery ... - Medgadget (blog) (NASDAQ:BIND)
www.medgadget.com - September 26 at 3:58 PM
nasdaq.com logoDelisting of Securities of BIND Therapeutics, Inc., InterCloud Systems, Inc., Echo Therapeutics, Inc., 1347 Capital ... - Nasdaq (NASDAQ:BIND)
www.nasdaq.com - September 25 at 3:35 PM
globenewswire.com logoDelisting of Securities of BIND Therapeutics, Inc., InterCloud Systems, Inc., Echo Therapeutics, Inc., 1347 Capital ... - GlobeNewswire (press release) (NASDAQ:BIND)
globenewswire.com - September 24 at 3:45 PM
openpr.com logoDemand for novel drug delivery systems are driving the Nanotechnology Market to reach US$ 11.9 Bn in 2023 (NASDAQ:BIND)
www.openpr.com - September 23 at 8:55 AM
News IconBIND Therapeutics Stipulation Approved - Bankrupt Company News (press release) (blog) (NASDAQ:BIND)
bankruptcompanynews.com - September 22 at 8:04 AM
4-traders.com logoAgios Pharmaceuticals : Appoints Andrew Hirsch as Chief Financial Officer (NASDAQ:BIND)
www.4-traders.com - September 21 at 8:23 AM
investingnews.com logoHow Do You Define Nanotechnology? - Investing News Network (press release) (registration) (blog) (NASDAQ:BIND)
investingnews.com - September 15 at 8:46 PM
News IconBIND Therapeutics Combined Plan Filed - Bankrupt Company News (press release) (blog) (NASDAQ:BIND)
bankruptcompanynews.com - September 15 at 8:46 PM
finance.yahoo.com logoHercules’ Leading Originations Platform Continues to Finance Some of the Most Promising Innovative and … (NASDAQ:BIND)
finance.yahoo.com - September 15 at 12:44 PM
News IconBIND Therapeutics Combined Plan Filed (NASDAQ:BIND)
bankruptcompanynews.com - September 15 at 12:44 PM
News IconBIND Therapeutics Extension Approved - Bankrupt Company News (press release) (blog) (NASDAQ:BIND)
bankruptcompanynews.com - September 14 at 3:50 PM
News IconProMIS Neurosciences announces positive validation of novel ... - Yahoo Sports (NASDAQ:BIND)
sports.yahoo.com - September 13 at 5:04 PM
News Icon'Leap of faith' in HIF leads to Lasker Award, clinical trials - BioWorld Online (NASDAQ:BIND)
www.bioworld.com - September 13 at 5:04 PM
finance.yahoo.com logoSiamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium - Yahoo Finance (NASDAQ:BIND)
finance.yahoo.com - September 13 at 8:43 AM
globenewswire.com logoBeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317 - GlobeNewswire (press release) (NASDAQ:BIND)
globenewswire.com - September 12 at 8:38 AM
prnewswire.com logoXencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute ... - PR Newswire (press release) (NASDAQ:BIND)
www.prnewswire.com - September 12 at 8:38 AM
News IconCantabio Pharmaceuticals licenses Tau protein targeting therapeutic program from University of Cambridge for the ... - EconoTimes (NASDAQ:BIND)
www.econotimes.com - September 7 at 3:51 PM
businesswire.com logoProclara Biosciences Announces $47 Million in New Investment to ... - Business Wire (press release) (NASDAQ:BIND)
www.businesswire.com - September 7 at 3:51 PM
News IconNew HIF-2 kidney cancer therapy more effective than current treatment, study shows (NASDAQ:BIND)
www.utsouthwestern.edu - September 6 at 8:40 PM

Social

What is DNIB Unwind's stock symbol?

DNIB Unwind trades on the NASDAQ under the ticker symbol "BIND."

Where is DNIB Unwind's stock going? Where will DNIB Unwind's stock price be in 2017?

5 analysts have issued 1 year target prices for DNIB Unwind's shares. Their predictions range from $3.75 to $6.00. On average, they expect DNIB Unwind's share price to reach $5.25 in the next twelve months.

When will DNIB Unwind announce their earnings?

DNIB Unwind is scheduled to release their next quarterly earnings announcement on Thursday, August, 4th 2016.

How do I buy DNIB Unwind stock?

Shares of DNIB Unwind can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of DNIB Unwind stock cost?

One share of DNIB Unwind stock can currently be purchased for approximately $0.87.

DNIB Unwind (NASDAQ:BIND) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for DNIB Unwind (NASDAQ:BIND)

Earnings History Chart

Earnings by Quarter for DNIB Unwind (NASDAQ:BIND)

Dividend History Chart

Dividend Payments by Quarter for DNIB Unwind (NASDAQ:BIND)

Last Updated on 2/19/2017 by MarketBeat.com Staff